Vyome Holdings (HIND) Free Cash Flow (2015 - 2026)
Vyome Holdings (HIND) posted quarterly Free Cash Flow of -$1.4 million for Q1 2026, down 605.52% year-over-year from $284057.4 in Q1 2025, and up 2.86% quarter-over-quarter from -$1.5 million in Q4 2025.
Vyome Holdings (HIND) Free Cash Flow (2015 - 2026) Analysis & Trends
Vyome Holdings' Free Cash Flow history runs 12 years deep, the most recent figure standing at -$1.4 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 605.52% year-over-year to -$1.4 million; the TTM figure through Mar 2026 stood at -$5.0 million (down 497.13% YoY), while the FY2025 annual figure was -$3.7 million, down 510.43% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$1.4 million, up from -$1.5 million in the prior quarter.
- The five-year high for Free Cash Flow was $4.3 million in Q3 2025, with the low at -$7.4 million in Q1 2022.
- The 5-year median for Free Cash Flow is -$2.5 million (2023), against an average of -$2.6 million.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow surged 202.39% in 2024, then tumbled 49704.51% in 2025.
- Vyome Holdings' Free Cash Flow stood at -$2.8 million in 2022, then gained by 11.71% to -$2.5 million in 2023, then soared by 99.88% to -$2968.0 in 2024, then sank by 49704.51% to -$1.5 million in 2025, then advanced by 2.86% to -$1.4 million in 2026.
- Business Quant data shows HIND's Free Cash Flow at -$1.4 million in Q1 2026, -$1.5 million in Q4 2025, and $4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Vyome Holdings | 16.07 Mn | 8.18 Mn | 11,658.00 | -903,712.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -903,712.00 |
| Jun 30, 2026 | -903,712.00 |
| Mar 31, 2026 | -1.44 Mn |
| Mar 31, 2026 | -1.44 Mn |
| Dec 31, 2025 | -1.48 Mn |
| Dec 31, 2025 | -1.48 Mn |
| Sep 30, 2025 | 4.34 Mn |
| Sep 30, 2025 | 4.34 Mn |
| Jun 30, 2025 | -6.41 Mn |
| Jun 30, 2025 | -6.41 Mn |
| Mar 31, 2025 | -203,533.00 |
| Mar 31, 2025 | -203,533.00 |
| Dec 31, 2024 | -2,968.00 |
| Dec 31, 2024 | -2,968.00 |
| Sep 30, 2024 | 2.82 Mn |
| Sep 30, 2024 | 2.82 Mn |
| Jun 30, 2024 | -1.36 Mn |
| Jun 30, 2024 | -1.36 Mn |
| Mar 31, 2024 | -2.07 Mn |
| Mar 31, 2024 | -2.07 Mn |